.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Emerging Treatment Paradigms for Advanced Lung Cancer

EP. 1: Impact of PACIFIC Trial on Locally Advanced NSCLC

February 26th 2019

EP. 2: The Role of Surgery in NSCLC Following PACIFIC Trial

February 26th 2019

EP. 3: Imaging Schedule Following CRT in Locally Advanced NSCLC

February 26th 2019

EP. 4: Biomarker Testing in Stage III NSCLC

February 26th 2019

EP. 5: Driver Mutations Trump PD-L1 Expression in Lung Adenocarcinoma

February 26th 2019

EP. 6: Choosing Therapy for Newly Diagnosed NonDriver NSCLC

February 26th 2019

EP. 7: Looking at the IMpower Data in NSCLC

February 26th 2019

EP. 8: CheckMate-227 and the Role of TMB in NSCLC

February 26th 2019

EP. 9: Treatment Options for mNSCLC After Progression

February 26th 2019

EP. 10: A Win for Small-Cell Lung Cancer: IMPOWER 133

February 26th 2019

EP. 11: ADRIATIC Trial in Locally Advanced Small-Cell Lung Cancer

February 26th 2019

EP. 12: Molecular Testing for NSCLC in 2019

February 26th 2019

EP. 13: Osimertinib, the Standard for EGFR+ NSCLC

February 26th 2019

EP. 14: Resistance Mechanisms in EGFR+ NSCLC

February 26th 2019

EP. 15: Available Therapies for ALK-Rearranged NSCLC

February 26th 2019

EP. 16: A Game-Changing Year for NSCLC

February 26th 2019